Colgate-Palmolive Company
NYSE:CLHousehold & Personal Products
-$0.71 today
- Market cap
- $78.58B
- Beta
- 0.32
- P/E (TTM)
- 34.5
- EPS (TTM)
- $2.60
- Dividend yield
- 2.33%
Volume 6.07M
Average 5.62M
CL Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Colgate-Palmolive CompanyNYSE: CL
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q3 FY2026 depreciation & amortization of $159M rose 0.6% year over year, behind the +6.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at +4.9% a year.
Context
- Depreciation & amortization amounted to 3.1% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.6% toward the trailing-twelve-month pace of +6.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 630M USD
- Year-over-year change
- +4.1%
- 4-year CAGR
- +3.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 630M | +4.1% |
| FY2024 | 2024-12-31 | 605M | +6.7% |
| FY2023 | 2023-12-31 | 567M | +4.0% |
| FY2022 | 2022-12-31 | 545M | -2.0% |
| FY2021 | 2021-12-31 | 556M | — |
Depreciation & Amortization vs competitors
How CL compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +6.3% is the 3rd highest of 7, against a peer median of +1.4%.
- Depreciation & amortization amounts to 3.0% of revenue for CL, versus a peer median of 3.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.21B USD | +11.4% | +5.2% | 3.6% | |
| FY2025 | €1.35B EUR | -23.0% | -3.6% | 2.7% | |
| LTM Jun 2026 | $725M USD | -14.5% | +2.2% | 4.4% | |
| LTM Sep 2026 | $643M USD | +6.3% | +4.9% | 3.0% | |
| LTM Sep 2026 | $569M USD | +0.0% | -4.7% | 3.7% | |
| LTM Sep 2026 | $265M USD | +19.9% | +1.5% | 3.7% | |
| LTM Sep 2026 | $250.1M USD | +2.8% | +4.1% | 4.0% | |
| Peer median (excluding CL) | — | +1.4% | +1.9% | 3.7% | |
Competitors are the stored peer set for CL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.34B | 1.97B | 2.46B | 3.05B | 2.13B |
| Depreciation & Amortization | 556M | 545M | 567M | 605M | 630M |
| Deferred Income Tax | (132M) | (78M) | (98M) | (77M) | (109M) |
| Stock-Based Compensation | 135M | 125M | 122M | 135M | 0 |
| Change in Working Capital | (197M) | (726M) | 455M | 344M | 284M |
| Accounts Receivables | (84M) | (227M) | (37M) | (56M) | (16M) |
| Inventory | (72M) | (333M) | 194M | (100M) | 109M |
| Accounts Payables | 0 | 0 | 0 | 516M | 251M |
| Other Working Capital | (41M) | (166M) | 298M | (16M) | (60M) |
| Other Non-Cash Items | 625M | 723M | 244M | 51M | 1.26B |
| Operating Cash Flow | 3.33B | 2.56B | 3.75B | 4.11B | 4.2B |
| Capital Expenditures | (567M) | (696M) | (705M) | (561M) | (564M) |
| Acquisitions (Net) | 0 | (809M) | 0 | 0 | (293M) |
| Purchases of Investments | (141M) | (470M) | (506M) | (574M) | (698M) |
| Sales of Investments | 141M | 322M | 502M | 564M | 752M |
| Other Investing Activities | (25M) | 52M | (33M) | 37M | (14M) |
| Investing Cash Flow | (592M) | (1.6B) | (742M) | (534M) | (817M) |
| Debt Repayment | (175M) | 1.65B | (314M) | (408M) | (456M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 101M |
| Common Stock Repurchased | (1.32B) | (1.31B) | (1.13B) | (1.74B) | (1.21B) |
| Dividends Paid | (1.68B) | (1.69B) | (1.75B) | (1.79B) | (1.82B) |
| Other Financing Activities | 400M | 400M | 398M | 547M | 132M |
| Financing Cash Flow | (2.77B) | (952M) | (2.79B) | (3.39B) | (3.26B) |
| Effect of Forex Changes | (15M) | (60M) | (19M) | (54M) | 67M |
| Net Change in Cash | (56M) | (57M) | 191M | 130M | 192M |
| Free Cash Flow | 2.76B | 1.86B | 3.04B | 3.55B | 3.63B |
Colgate-Palmolive Company
NYSE:CL
Intrinsic Alpha fair value
Locked
Current Price
$98.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.